Issue Date: December 9, 2013
Juno Makes A Grand Entrance
Juno Therapeutics, a Seattle-based company focused on cancer immunotherapy, has debuted with a whopping $120 million in financing, one of the biggest-ever initial funding rounds for a biotech firm. Backed by Arch Venture Partners and the Alaska Permanent Fund, the company brings together technology developed at previously rival academic institutions to compete in a hot area of drug development.
With technology from Fred Hutchinson Cancer Research Center, Memorial . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society